Rycarfa 50 mg Tablets for Dogs

Quốc gia: Vương quốc Anh

Ngôn ngữ: Tiếng Anh

Nguồn: VMD (Veterinary Medicines Directorate)

Thành phần hoạt chất:

Carprofen

Sẵn có từ:

Krka d.d., Novo Mesto

Mã ATC:

QM01AE91

INN (Tên quốc tế):

Carprofen

Dạng dược phẩm:

Tablet

Loại thuốc theo toa:

POM-V - Prescription Only Medicine – Veterinarian

Nhóm trị liệu:

Dogs

Khu trị liệu:

Anti Inflammatory NSAID

Tình trạng ủy quyền:

Authorized

Ngày ủy quyền:

2014-04-03

Đặc tính sản phẩm

Revised: February 2019
AN: 00114/2018
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rycarfa 50 mg tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCE:
Carprofen
50.00 mg
EXCIPIENTS:
Ferric oxide red (E172)
1.52 mg
Ferric oxide black (E172)
0.95 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Tablet.
Round, dark brown, marbled tablets with visible darker spots, one-side
scored and
bevel-edged.
The tablet can be divided into equal parts.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculoskeletal disorders
and
degenerative joint disease. As a follow up to parenteral analgesia in
the management
of post-operative pain.
4.3
CONTRAINDICATIONS
Do not use in cats.
Do not use in pregnant or lactating bitches.
Do not use in dogs less than 4 months of age.
Do not use in cases of hypersensitivity to the active substance or to
any of the
excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is a
possibility of gastrointestinal ulceration or bleeding, or where there
is evidence of a
blood dyscrasia.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Revised: February 2019
AN: 00114/2018
Page 2 of 5
Refer to Sections 4.3 and 4.5.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Use in aged dogs may involve additional risk.
If such a use cannot be avoided, dogs may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a
potential risk of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should be instigated.
See section 4.8.
The tablets are flavoured. In order to avoid any accidental ingestion,
store tablets out
of reach of the animals.
Special